NHS Claims 29 Hospital Trusts Benefit From Palantir AI Platform Despite Zero Active Use

In response, NHS England maintained that trusts reporting benefits include those utilizing backend tools for data submission and analysis rather than direct clinical care. For instance, Torbay and South Devon NHS Foundation Trust noted that while infrastructure is set up to support data submission, it is not actively using FDP operational apps.

The discrepancy has drawn criticism from industry representatives and regulators. Marc Farr, chair of the NHS Chief Data and Analytics Officers Network, stressed the necessity of accurate and verifiable benefit reporting. Simultaneously, the Office for Statistics Regulation (OSR) is investigating NHS England’s performance claims under its casework function, following admissions earlier this summer that the health authority could not prove cause and effect regarding its claim of 117,539 additional operations carried out at participating trusts.

Political Pressure and Palantir's Defence

The findings have amplified calls from campaigners and politicians for Health Secretary Yvette Cooper to reconsider the government's deal with the US technology firm. Chi Onwurah, chair of the Commons science and technology committee, questioned whether the reality of Palantir's software matches its surrounding hype, advocating for ministers to invoke a 2027 break clause in the contract to allow a UK-owned supplier to handle patient data.

Palantir has aggressively defended its record and software efficacy. A spokesperson for the company stated that the platform has contributed to 117,000 additional operations, a 14.3% reduction in discharge delays for long-stay patients, and a 5.6% improvement in 28-day cancer diagnosis notifications. Louis Mosley, Palantir’s chief executive for the UK and Europe, argued that canceling the deal would put "politics above patients" and accused critics of "Palantir Derangement Syndrome."

To bolster its position, Palantir recently hired former Labour deputy leader Lord Tom Watson as a senior lobbyist to address concerns regarding vendor lock-in. However, direct outreach to MPs by Watson and Mosley has sparked further friction, with Labour MP Clive Lewis describing targeted communications tracking parliamentary statements as "very Big Brother." The software vendor also faces broader political scrutiny over its external contracts with the Israeli military and US Homeland Security, alongside past public statements by billionaire founder Peter Thiel questioning democracy.

What it means for developers

For software engineers, data architects, and technical leaders, the NHS Palantir controversy highlights critical challenges in large-scale software rollouts and data platform integration.

• Defining Deployment vs. Active Use: Classifying a system as "live" simply because backend data submission pipelines exist can mask zero adoption at the end-user level. Developers building enterprise solutions must track active usage metrics rather than relying on infrastructure connectivity as a proxy for success.
• Attribution and Telemetry: Claiming high-level outcomes—such as reduced discharge delays or increased throughput—requires clear telemetry and verifiable causality. System architects need evaluation frameworks that isolate a platform's direct impact from broader organizational variables.
• Avoiding Vendor Lock-in: Enterprise deployments often run into friction when proprietary platforms face political or operational hurdles. Technical teams evaluating machine learning capabilities benefit from testing multiple model architectures flexibly. Developers looking to benchmark and prototype with diverse AI engines can try top AI models cheaply through one API at https://apixoai.online, helping teams maintain operational flexibility without committing to restrictive enterprise infrastructure upfront.
• Verifiable Metrics: Overstating application benefits or relying on creative reporting erodes trust with end users, domain experts, and regulatory oversight bodies.

Source: Palantir AI tech unused or little used by 29 NHS trusts said to be benefiting from it — The Guardian AI. Written by the Apixo team from that report.